{
    "organizations": [],
    "uuid": "fb04b5840d148b4ff0d635bb4ae21839ddb89f7d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-sienna-biopharma-announces-first-p/brief-sienna-biopharma-announces-first-patient-dosed-in-first-in-human-trial-of-topical-sna-125-idUSFWN1Q41A4",
    "ord_in_thread": 0,
    "title": "BRIEF-Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 14, 2018 / 2:17 PM / in 9 minutes BRIEF-Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125 Reuters Staff Feb 14 (Reuters) - Sienna Biopharmaceuticals Inc: * SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN FIRST-IN-HUMAN TRIAL OF TOPICAL SNA-125 * SIENNA BIOPHARMACEUTICALS INC - TOP-LINE RESULTS FROM STUDY EXPECTED IN Q3 OF 2018 * SIENNA BIOPHARMACEUTICALS INC - PLAN TO INITIATE SNA-125 PROOF-OF-CONCEPT TRIAL FOR ATOPIC DERMATITIS AND EXPECT THOSE DATA IN SECOND HALF OF 2018 * SIENNA BIOPHARMACEUTICALS- EXPECT TO REPORT TOP-LINE DATA IN 1H 2019 FROM SNA-120 PHASE 2B CLINICAL TRIAL FOR PRURITUS & ASSOCIATED UNDERLYING PSORIASIS Source text for Eikon: Further company coverage:",
    "published": "2018-02-14T16:14:00.000+02:00",
    "crawled": "2018-02-14T16:34:12.043+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "biopharma",
        "announces",
        "first",
        "patient",
        "dosed",
        "trial",
        "topical",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "sienna",
        "biopharmaceuticals",
        "inc",
        "sienna",
        "biopharmaceuticals",
        "announces",
        "first",
        "patient",
        "dosed",
        "trial",
        "topical",
        "sienna",
        "biopharmaceuticals",
        "inc",
        "result",
        "study",
        "expected",
        "q3",
        "sienna",
        "biopharmaceuticals",
        "inc",
        "plan",
        "initiate",
        "trial",
        "atopic",
        "dermatitis",
        "expect",
        "data",
        "second",
        "half",
        "sienna",
        "expect",
        "report",
        "data",
        "1h",
        "phase",
        "2b",
        "clinical",
        "trial",
        "pruritus",
        "associated",
        "underlying",
        "psoriasis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}